Article

Cluster protocols in SCIT: enough evidence for practical use?

Centre for Rhinology and Allergology (Wiesbaden) of the Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, D-65183 Wiesbaden, Germany.
Current Opinion in Allergy and Clinical Immunology (Impact Factor: 3.66). 06/2010; 10(3):188-93. DOI: 10.1097/ACI.0b013e328339505c
Source: PubMed

ABSTRACT The review provides a comprehensive evaluation of Cluster schedules in subcutaneous-specific immunotherapy (SCIT) in terms of the safety profile and onset of clinical and immunological effects.
Recent major clinical studies could clearly reveal that Cluster schedules with both (semi-)depot-allergen preparations and chemically modified allergen preparations ('allergoids') are well tolerated therapeutic options in SCIT comparable to the safety profile of conventional build-up schedules. Moreover, preliminary data indicate that these accelerated protocols result in a more rapid achievement of clinical and immunological effects.
Conventional schedules in SCIT have the disadvantage of both a high expenditure of time and the need for a high patient compliance. In accelerated cluster schedules two to three injections are administered sequentially per treatment day (with an interval of 30 min between the injections) in weekly intervals aimed to reach the maintenance dose of SCIT in a short time interval. Recent studies indicate that these accelerated SCIT protocols result in a more rapid achievement of clinical and immunological effects than conventional schedules. Moreover, the safety profile is comparable between conventional and cluster SCIT.

0 Followers
 · 
90 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: The conventional schedule used in specific subcutaneous immunotherapy (SCIT) is a slow treatment that often leads to poor compliance or discontinuation of treatment. These disadvantages have led to design administration schedules that shorten the build-up phase without increasing the adverse reactions rate. AREAS COVERED: This report reviews the available scientific documentation of the safety profile of build-up schedules for SCIT with Alustal Rapid® (a suspension of standardized allergen extracts adsorbed on aluminum hydroxide gel for specific immunotherapy) in the treatment of IgE-mediated rhinitis, conjunctivitis and bronchial asthma to inhaled allergens. EXPERT OPINION: Cluster and shortened conventional schedules may offer a safe method of SCIT for the treatment of respiratory allergy and reduce the inconvenience associated with conventional schedules by reaching the maintenance dose in less time and with fewer visits; thereby this method could reduce discontinuation rates and increase compliance.
    Expert Opinion on Drug Safety 07/2011; 10(6):947-55. DOI:10.1517/14740338.2011.603724 · 2.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Allergen subcutaneous immunotherapy is a long lasting treatment which can modify the natural history of allergic respiratory diseases. Recommended administration is required for a minimum of three years. During this long term therapy the daily management is based on two crucial points, discussed in this review, such as the prevention and the treatment of side effects and the improvement and follow-up of patient adherence. This review specifically focuses on subcutaneous immunotherapy.
    European annals of allergy and clinical immunology 10/2011; 43(5):135-40.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To update safety information regarding allergen-specific immunotherapy (ASIT) in clinical practice and highlight the risk factors associated with the adverse reactions, product and each dose. Efforts in recent years have focused on increasing our understanding of the efficacy and safety of ASIT, especially the sublingual variety (SLIT), in multicenter studies. Moreover, new Clinical Practice Guidelines (CPGs) and an international consensus concerning ASIT have been published recently. Although no deaths as a result of subcutaneous immunotherapy or SLIT have been reported in the last 2 years, systemic reactions mainly arising from administration errors still appear. Recent studies support the safety of new forms of specific immunotherapy. An understanding of the risk factors for each patient, product and dose, and the implementation of CPGs are the main factors that could improve the safety of ASIT. The standardization of all procedures for prescribing and administering ASIT, and the systematic collection of standardized safety data in a multicenter database (postmarketing surveillance), may be required to generate new information on the safety of ASIT.
    Current Opinion in Allergy and Clinical Immunology 12/2011; 11(6):579-85. DOI:10.1097/ACI.0b013e32834c229e · 3.66 Impact Factor